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Abstract. Pomegranate has been used therapeutically for 
centuries. The aim of the present study was to examine the 
effects of pomegranate juice (PJ) supplementation on complete 
blood count (CBC), glucose, blood lipids and C‑reactive protein 
(CRP) in healthy subjects. A total of 5 males and 5 females 
(aged 31.8±6.6 years, weighing 66.2±12.9 kg) were randomly 
assigned into one of two groups and either consumed 500 ml 
PJ/day or no PJ for 14 days. Blood samples were obtained from 
participants prior to and following the experimental period. PJ 
consumption resulted in a significant increase in red blood cell 
count (P<0.05), hemoglobin levels (P<0.001) and hematocrit 
levels (P<0.05). Other CBC parameters, glucose, cholesterol, 
triglycerides, high‑density lipoprotein, low‑density lipopro‑
tein and CRP levels did not significantly change following 
PJ consumption. These results indicate that PJ intake for a 
short period of time may result in increased erythropoiesis or 
decreased degradation without any significant alterations in 
factors associated with metabolic health and inflammation in 
healthy individuals.
Introduction
Pomegranate is a fruit that has been cultivated for centu‑
ries and is considered of high nutritional and therapeutic 
value (1). Its biological and therapeutic properties are 
primarily attributed to the presence of polyphenols 
(ellagitanins, flavonoids, phenolic acids, stilbenes, tannins 
and anthocyanins) (2,3), which are free radical scavenging 
compounds (4). Pomegranate is also rich in vitamins and 
minerals (5). Generally, pomegranate juice (PJ) is the greatest 
contributor to pomegranate ingestion in daily nutrition. 
Notably, the in vitro antioxidant activity of PJ has been 
determined to be threefold higher compared with red wine 
and green tea and is typically more potent than that of other 
natural juices (6,7).
Based on phytochemical compounds and their activity in 
PJ, research on the effects of PJ supplementation on health 
parameters has provided promising results regarding oxida‑
tive stress, inflammation and metabolic diseases (8). These 
studies have been conducted in vitro (9), in animals (10) 
and humans (11,12). Research conducted on atherosclerotic 
mice indicated that PJ supplementation reduced the size 
of atherosclerotic lesions and inhibited disease progres‑
sion (13‑15). Research on patients with cardiovascular disease 
demonstrated that following PJ supplementation, low density 
lipoprotein (LDL) levels were reduced (16,17), stress induced 
ischemia (18) and vascular thickness decreased (19), while 
positive findings were particularly evident in patients at higher 
risk of coronary heart disease (20). In healthy individuals, 
PJ consumption reduced the potential for LDL aggregation, 
which represents an important step towards formation of foam 
cells and thus vascular thrombi (13). Furthermore, it has been 
indicated that PJ intake on a regular basis may affect choles‑
terol metabolism in macrophages, leading to reduced cellular 
uptake of oxidized LDL (12). PJ is also able to reduce nitric 
oxide synthase expression in endothelial cells of coronary 
vessels (15). In 2001, Das et al (21) examined the effect of 
pomegranate seed extract ingestion in diabetic rats. The results 
indicated that there was a significant decrease in glucose levels 
of ~50%, 12 h after taking the extract, regardless of the dose 
given (300 and 600 mg/kg). These findings may be the result 
of an increased absorption of glucose by peripheral tissues, 
which is associated with the presence of polyphenols in pome‑
granate and their function (22).
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Studies in humans and mice demonstrated that even 
moderate PJ consumption reduced susceptibility to free 
radical lipid peroxidation, while it increased resistance to LDL 
and high density lipoprotein (HDL)‑cholesterol oxidation (23). 
Inhibition of lipid peroxidation with PJ supplementation 
has been verified in carotid artery stenosis patients (18), 
type II diabetics (12) and healthy individuals (3). In 2014, 
Matthaiou et al (3) also determined that glutathione (GSH) 
levels were increased following two weeks PJ supplementation, 
indicating that PJ induced beneficial changes in erythrocyte 
antioxidant concentration. In 2009, Boussetta et al (24) 
reported that punicic acid, a conjugated unsaturated fatty 
acid which is derived from the oil of pomegranate seeds, has 
anti‑inflammatory action due to its potential to reduce the 
activity of neutrophils. Specific tannins in pomegranate also 
exhibited anti‑inflammatory action in mice (25).
Although there have been numerous studies reporting the 
benefits of the polyphenols contained in PJ on health parameters 
in those with various diseases, research on healthy humans is 
scarce. The antioxidant properties of polyphenolic flavonoids 
may enhance cell resistance to oxidative stress, including red 
blood cells; however, to the best of our knowledge, the effects 
of PJ consumption on complete blood counts (CBC) have not 
been investigated. Therefore, the purpose of the present study 
was to examine the effects of PJ supplementation on CBC, in 
addition to glucose, blood lipids and C‑reactive protein (CRP) 
levels in healthy individuals.
Material and methods
Participants. A total of 10 healthy and recreationally active 
individuals (5 males and 5 females) aged 31.8±6.6 years and 
weighing 66.2±12.9 kg were recruited for the current study 
through flyers and word of mouth in the region of Thessaly, 
Greece. Power analysis was run using G*Power Data Analysis 
(Heinrich‑Heine‑University Düsseldorf, Düsseldorf, Germany) 
to estimate the required sample size. It was calculated that the 
necessary sample size was n=10 for statistical power 0.8, P<0.05 
and effect size 0.4. Although the majority of previous studies 
on PJ supplementation have used 14‑18 subjects, the sample 
size of the present study is enough to support the findings. 
Inclusion criteria included the absence of any clinical symptom 
or chronic disease as determined by a health questionnaire. 
Exclusion criteria included the presence of gastrointestinal 
or metabolic disease, the taking of any medication (including 
nutritional supplements such as vitamins, minerals and phytos‑
terols), smoking, current pregnancy or lactation in women or the 
following of a specific diet regime. Written informed consent 
was obtained from all participants when they had been informed 
of all risks, discomforts and benefits involved with the current 
study. The procedures were in accordance to the 1975 Helsinki 
declaration and were approved by the Institutional Review 
Board of the University of Thessaly (Larissa, Greece).
Study design. During the first visit, participants received 
information regarding the trial, completed a health and a 
physical activity questionnaire and signed the consent form. A 
randomized, counterbalanced, within‑subjects experimental 
design was applied and participants were randomly assigned 
into two groups (each, n=5). One group consumed 500 ml/day 
PJ for fourteen days (the experimental group); the other group 
consumed no PJ for fourteen days (the control group). The four 
experimental weeks were separated by a one‑week washout 
period. All participants reported to the laboratory at the 
start and the end of each two‑week phase. In each test day 
at the two‑week time point, anthropometric and physiological 
measurements in addition to blood sampling took place from 
8‑10 a.m., following an overnight fast. Alcohol consumption 
and smoking were not allowed for 12 h prior to each test day. 
Water consumption was ad libitum. All measurements were 
performed under controlled environmental conditions (the 
room temperature was 22±2˚C, with a relative humidity of 
45±4%).
Anthropometric and physiological measurements. Body mass, 
body fat and hydration level were assessed using leg‑to‑leg 
bioelectrical impedance scale (Tanita BF 522 W; Tanita 
Europe BV, Amsterdam, The Netherlands) while participants 
were lightly dressed and barefooted. Standing height was 
measured to the nearest 0.1 cm (Stadiometer 208, Seca GmbH, 
Hamburg, Germany). Body mass index (BMI) was calculated 
using the equation BMI=weight (kg)/[height (m)]2. Waist 
and hip circumferences were obtained with measuring tape. 
Waist to hip ratio (WHR) was calculated using the equation 
WHR=waist circumference/hip circumference. Blood pres‑
sure (BP) was measured with a manual sphygmomanometer 
(FC‑101 Aneroid Sphygmomanometer; Focal Corporation, 
Tokyo, Japan); the lowest of three readings was recorded. 
Baseline anthropometric and physiological characteristics of 
all participants are presented in Table I.
Diet and physical activity. To ensure that diet and/or exercise 
preceding the trials would not affect biochemical parameters 
measured in the current study, participants were instructed 
to refrain from excessive exercise, record meals and physical 
activity two days prior to the first trial, and follow the same 
diet and activities for two days prior to each subsequent 
trial. Each participant was provided with a written set of 
guidelines and record sheets for recording food intake and 
physical activity. Diet records were subsequently analyzed 
using the computerized nutritional analysis system Science Fit 
Diet 200A (Science Technologies, Athens, Greece; Table II). 
Participants were instructed to follow their usual habits during 
the experiment otherwise.
Test food. The juice tested was a commercially available 
product (CBH‑VITOM S.A., Athens, Greece). PJ was provided 
to the participants in bottles containing 250 ml each and the 
participants were instructed to consume one in the morning 
and one in the afternoon (a total of 500 ml per day). Each 
250 ml product was prepared from 2.5 squeezed pomegran‑
ates. Nutritional values per 100 ml and as percentages of the 
Recommended Daily Allowance are presented in Table III. 
The polyphenolic composition of the PJ was measured by 
Matthaiou et al (3), as the PJ was the same as the one used in 
the present study. Briefly, the total polyphenolic content was 
405.00 mg/l of equivalent gallic acid and the total amount 
of flavonoid was 12.67 mg/l of equivalent quercetin. PJ also 
contained different classes of polyphenols as flavonoids, 
phenolic acids and stilbenes. The concentrations of the 
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polyphenols contained in the PJ used in the current study 
were comparable to those identified in previous studies (26). 
However, total polyphenols in PJ may vary significantly 
between different pomegranate cultivars (27).
Blood collection and analyses. Participants rested in the lab 
for 30 min prior to blood sample being obtained. Participants 
were in a seated position when 20 ml blood was drawn from 
the forearm vein. A portion (1‑2 ml) of the blood collected 
was used to determine the parameters of the CBC measured 
by an automatic hematology analyzer (Mythic™ 18; Orphee 
Medical SA, Geneva, Switzerland). Each measurement was 
performed twice. The remaining blood was centrifuged at 
4˚C, 1370 x g for 10 min to separate the plasma in a refriger‑
ated centrifuge (Heraeus™ Biogigure Primo; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). Then the collected super‑
natant was transferred to Eppendorf tubes (Sarstedt AG & Co., 
Numbrecht, Germany). The samples were stored at ‑80˚C and 
thawed only once prior to analysis. Glucose, total cholesterol, 
HDL‑cholesterol and triglyceride concentrations in plasma 
Table II. Nutritional analysis of the 2‑day diet records of all participants, in the experimental and control groups. 
 EG CG
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Component Pre Post Pre Post
Energy, kcal 1771.5±425.1 1765.8±403.0 1737.8±398.2 1783.8±406.4
Protein, g 74.3±24.1 71.4±25.7 73.8±25.7 73.5±23.3
Carbohydrate, g 194.2±59.6 193.3±40.4 199.1±68.4 200.7±69.9
Fat, g 73.3±22.7 75.8±18.1 71.7±21.0 75.1±24.1
Cholesterol, mg 246.9±143.1 240.3±127.2 250.9±148.1 228.5±110.1
Fiber, g 15.8±8.4 16.3±8.4 15.5±9.9 15.8±10.2
Vitamin A, IU 4,264.5±2,193.9 4,443.4±2,895.5 4,513.9±2,917.1 4,527.7±2,854.3
Vitamin B12, µg 3.5±1.5 3.6±1.7 3.4±2.1 3.6±1.5
Vitamin B6, mg 1.8±0.5 1.9±0.6 1.7±0.7 1.8±0.5
Vitamin C, mg 79.3±36.4 77.6±29.0 76.6±33.6 71.5±34.5
Vitamin D, mg) 114.1±81.3 116.3±75.0 105.9±69.7 100.9±56.1
Vitamin E, mg_RE 8.7±10.5 9.0±9.9 8.6±11.0 8.2±8.9
Thiamine, mg 2.7±1.4 2.4±1.2 2.2±1.4 2.6±1.3
Niacin, mg 21.8±7.9 21.0±8.3 19.6±6.9 21.1±6.8
Pantothenic Acid, mg 11.0±20.6 10.2±17.3 12.1±25.9 10.3±19.1
Riboflavin, mg 2.4±1.9 2.6±1.7 2.3±1.6 2.2±1.3
Folate, µg 351.6±106.4 345.5±103.7 346.8±138.8 335.9±87.5
Iron, mg 14.0±3.2 14.7±4.3 14.7±4.6 14.5±2.7
Selenium, µg 110.4±33.6 105.0±40.5 106.5±44.7 103.4±39.4 
Data are presented as mean ± standard deviation. EG, experimental group; CG, control group. 
Table I. Baseline anthropometric and physiological characteristics of all participants before and after the experimental period.
 EG CG
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Characteristic Pre Post Pre Post
Weight, Kg 66.5±13.0 66.3±12.6 66.3±12.9 65.8±12.6
Body Fat, % 21.5±3.3 21.3±3.1 20.4±4.0 20.0±4.4
WHR 0.80±0.1 0.79±0.1 0.80±0.1 0.79±0.1
SBP, mmHg 107.0±9.8 106.5±8.5 108.0±9.5 103.0±10.6
DBP, mmHg 70.5±6.4 71.0±6.1 69.5±8.3 67.5±8.6
Heart rate, bpm 75.3±10.3 73.4±10.1 78.1±9.1 73.5±11.3
Hydration state, % 54.3±1.3 54.3±1.8 54.6±2.0 54.4±2.0 
Data are presented as mean ± standard deviation. EG, experimental group; CG, control group; WHR, waist to hip ratio; SBP, systolic blood 
pressure; DBP, diastolic blood pressure.
MANTHOU et al:  POMEGRANATE JUICE ON BIOCHEMICAL PARAMETERS AND COMPLETE BLOOD COUNT4
were determined using a biochemical analyzer (Clinical 
Chemistry Analyzer Z 1145; Zafiropoulos Diagnostica S.A., 
Koropi, Greece). LDL‑cholesterol was calculated using the 
Friedewald equation (28). CRP was analyzed by a semi‑quan‑
titative method using a commercial available kit (CRP Latex 
Slide Test, Code 7300; Zafiropoulos Diagnostica S.A., Koropi, 
Greece) according to the principal of the latex agglutination 
assay described by Singer et al (29).
CBC test included: White blood cell (WBC), lymphocytes 
(LYM), monocytes (MON), granulocytes (GRA), lympho‑
cyte percentage (LYM%), monocyte percentage (MON%), 
granulocyte percentage (GRA%), red blood cell (RBC) count, 
hemoglobin (HGB), hematocrit (Hct), mean corpuscular 
volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), red blood 
cell distribution width (RDW), platelets (PLT), mean platelet 
volume (MPV), plateletcrit (PCT) and platelet distribution 
width (PDW).
Statistical analysis. Analysis of data was performed with 
two‑way (group x time) repeated measures analysis of variance. 
If a significant interaction was obtained, pairwise comparisons 
were performed through simple main‑effect analysis using the 
Bonferroni test method. P<0.05 was considered to indicate 
a significant difference. The statistical programme used was 
SPSS version 18 (SPSS Inc., Chicago, IL, USA). Results are 
presented as mean ± standard deviation.
Results
General characteristics. Compliance with PJ consumption 
was 97.9%. Anthropometric characteristics of participants did 
not change markedly during the 5‑week experimental period. 
Analysis of the diet records did not reveal any significant 
difference in the macro and micronutrients of the groups prior 
to each blood sampling (Table II). No significant changes 
for group or group x time were identified for RBC count. 
However, there were significant differences with respect to 
time (F1,18=4.42; P<0.05). Pairwise comparison demonstrated 
a significant increase (P<0.05) in the RBC count following PJ 
supplementation, which did not occur in individuals in the 
control group (Fig. 1A).
CBC parameters. No significant results for group or group 
x time were identified for hemoglobin. However, there were 
significant differences with respect to time (F1,18=5.12, 
P<0.05). Pairwise comparison indicated a significant increase 
(P<0.001) in the concentration of hemoglobin following PJ 
supplementation, which did not occur in individuals in the 
control group (Fig. 1B).
No significant results for group or group x time were 
identified for hematocrit. However, there were significant 
differences with respect to time (F1,18=4.27, P<0.05). Pairwise 
comparison indicated a significant increase (P<0.05) in hema‑
tocrit following PJ supplementation (Fig. 1C).
The remaining CBC parameters prior to and following 
completion of the two trials are presented in Table IV. In 
general, these parameters did not change in either group. 
A significant difference was observed for group x time 
(F1,17=3.98, P<0.05) in MCHC only. Pairwise comparison 
demonstrated a significant increase (P<0.05) in MCHC in the 
control group at the end of the experimental period (Table IV).
Biochemical parameters. Furthermore, PJ supplementation 
did not significantly alter the concentrations of total choles‑
terol, HDL, LDL, glucose and triglycerides (Table V). CRP 
values were not >6 mg/dl, indicating decreased inflammation 
either at baseline or following the experimental period.
Discussion
The results of the present study demonstrate that PJ consump‑
tion of 500 ml/day for two weeks increased the RBC count, 
hemoglobin concentration and hematocrit in healthy indi‑
viduals. Other parameters concerning complete blood count, 
metabolic health or inflammation were not altered in this 
cohort of individuals. Therefore, PJ intake for a short period 
of time may result in increased erythropoiesis or prevention of 
RBC degradation without any significant alterations in factors 
associated with metabolic health and inflammation in healthy 
individuals.
RBCs and hemoglobin constitute the transport system of 
oxygen from the lungs to the tissues. It has been demonstrated 
that a high concentration of polyphenols may increase the 
resistance of RBC to oxidative stress (30). Therefore, a poten‑
tial explanation for the results of the current study is that the 
increased content of polyphenols in PJ may have prevented RBC 
destruction due to reduced oxidative stress. Indeed, this hypoth‑
esis is further supported by a study reporting higher reduced 
GSH levels in erythrocytes following 500 ml PJ supplementation 
every day for two weeks (3). It was noted that this increase may 
be due to the induction of expression or the catalytic activity of 
enzymes involved in GSH biosynthesis that are known to be 
increased by plant polyphenols (31).
Similarly, the participants that consumed PJ exhibited a ~3% 
increase in hemoglobin by at the end of the two week interven‑
tion. This finding is particularly important considering the short 
period during which participants consumed the juice. It has been 
determined that flavonoids serve an important role in preventing 
oxidation of hemoglobin by various factors, such as hypochlo‑
rous acid (32). Flavonoids bind to hemoglobin and are able 
to inhibit oxidation of the hemoglobin molecule by oxidizing 
agents. In addition to flavonoids, PJ exhibits antioxidant activity 
Table III. Nutritional values of pomegranate juice per 100 ml 
and as percentages of the RDA.
Component Per 100 ml % RDA (250 ml)
Energy, kcal 58   7
Protein, g   0.3   2
Carbohydrate, g 14.1 12
Sugars, g 11.6 ‑
Fat, g   0.3   1
Saturated Fat, g   0.0   0
Fiber, g   0.1   3
Salt, mg     0.01   1
RDA, recommended daily allowance.
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that is much higher than that of red wine, green tea and other 
natural juices (4). Antioxidant capacity in erythrocytes has been 
identified to increase following two weeks of PJ supplementation 
in healthy individuals (3). Therefore, a potential explanation for 
the increased hemoglobin levels observed in the current study 
may be that the phytochemicals contained in PJ juice may have 
protected hemoglobin from oxidizing agents.
Hematocrit also exhibited a significant increase following 
two weeks of PJ supplementation. Increasing levels of hematocrit 
may be due to reduced RBC destruction. The high concentra‑
tion of antioxidants in PJ is likely to have protected RBC and 
resulted in their subsequent reduced destruction. However, the 
measurements completed in the present study cannot confirm 
which factors caused this change. Therefore, further studies are 
required to highlight the contribution and importance of each 
factor, in addition to any potential synergistic effect.
Other parameters of the CBC did not change significantly 
over the course of PJ supplementation, with the exception 
of MCHC levels, which were significantly increased in the 
control group at the end of the experimental period. MCHC 
is an indicator of the average density of hemoglobin per RBC 
medium and usually increases in dehydration and hereditary 
spherocytosis, sickle cell disease and homozygous hemoglobin 
C disease (33). The change in MCHC was significant only for 
individuals in the control group. It may be suggested that the 
increase in MCHC levels is due to dehydration in the control 
group. However, assessment of hydration status performed 
through bioelectrical impedance (Table I) did not identify any 
significant differences over time or between groups. Indeed, this 
is something that requires further investigation.
Lipid profile was not altered following supplementation 
of PJ. Previous studies have reported that pomegranate may 
reduce blood lipid levels and lipid peroxidation (3,34). In 
diabetic subjects with hyperlipidemia, consumption of PJ 
concentrate for 8 weeks significantly reduced levels of total 
cholesterol and LDL (16,17). The absence of any significant 
changes in the present study may be due to the short duration 
of supplementation. Also, participants in the current study were 
individuals with normal lipid levels compared with previous 
studies where participants had elevated lipid levels (15,16). A 
previous study has demonstrated that the higher the cardiovas‑
cular risk, the greater the changes occurring in risk factors such 
as cholesterol (20). Individuals in the current study were also 
normoglycaemic and CRP was within normal levels at baseline. 
Therefore, this may determine why changes in glucose and CRP 
were not evident in either group, although a decrease in both 
parameters has previously been recorded in rats following PJ 
supplementation (21,24). Finally, studies investigating a greater 
number of participants would provide more reliable results on 
the effects of PJ supplementation in various health parameters.
PJ supplementation may result in an increased RBC count, 
hemoglobin concentration and hematocrit in healthy individuals. 
Figure 1. Changes in (A) RBC, (B) hemoglobin and (C) hematocrit following PJ consumption. *P<0.05 vs. Pre of the same group. RBC, red blood cell; 
PJ, pomegranate juice.
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Therefore, PJ supplementation may affect factors involved either 
in RBC formation and erythropoiesis, or in prevention of RBC 
degradation. It has been postulated that increased generation of 
ROS may contribute to the shorter lifespan of RBCs associated 
with iron‑deficiency anemia (35). Therefore, antioxidants such 
as polyphenols may help counterbalance increased oxidative 
stress in RBCs, thus preventing their degradation. PJ is a rich 
source of polyphenols and nutrients and may therefore aid 
RBCs and other cells to counterbalance oxidative stress. Further 
research on this topic may reveal if PJ may be used as an adjunc‑
tive strategy for the prevention or treatment of certain types 
of anemia. In conclusion, two weeks of PJ supplementation 
resulted in an increased RBC count, hemoglobin concentration 
and hematocrit in healthy individuals. Due to the confirmed 
functional properties of PJ, further research is required to deter‑
mine the long‑term effects of PJ supplementation on healthy 
individuals in addition to the effect of different amounts of PJ 
on various biomedical parameters. Furthermore, it is necessary 
to investigate the effect of supplementation of PJ on factors 
affecting RBC formation and erythropoiesis, or prevention of 
RBC degradation.
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hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood cell distribution width; PLT, platelets; MPV, mean platelet 
volume; PCT, plateletcrit; PDW, platelet distribution width.
Table V. Biochemical parameters of all participants in the experimental and control groups. 
 Control Pomegranate
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Parameter, mmol/l Pre Post Pre Post
TG  0.92±0.14 0.87±0.12 0.91±0.12 0.95±0.14
TC 4.9±0.3 5.1±0.3 5.0±0.3 5.1±0.3
HDL 1.51±0.09 1.55±0.12 1.53±0.11 1.57±0.12
LDL 2.98±0.31 3.15±0.30 3.07±0.31 3.05±0.29
Glucose 5.3±0.1 5.2±0.1 5.2±0.1 5.1±0.1
Data are presented as mean ± standard deviation. TG, triglycerides; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density 
lipoprotein.
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